Publications
Selected Publications
Last 3 Years
2021
114. Del Papa, J., R.G. Clarkin, R.J. Parks (2021) Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic. Cancer Gene Therapy 28:745-756. doi: 10.1038/s41417-020-0192-9.
115. Warman Chardon, J., B.J. Jasmin, R. Kothary and R.J. Parks (2021) Report on the 5th Ottawa International Conference on Neuromuscular Disease and Biology - October 17-19, 2019, Ottawa, Canada. Journal of Neuromuscular Diseases. 8(2):323-334. doi: 10.3233/JND-219001.
116. Saha, B. and R.J. Parks (2021) Identification of human adenovirus replication inhibitors from a library of small molecules targeting cellular epigenetic regulators. Virology 555:102-110. doi: 10.1016/j.virol.2020.07.007.
117. René, C.A. and R.J. Parks (2021) Delivery of therapeutic agents to the central nervous system and the promise of extracellular vesicles. Pharmaceutics 13(4):492. doi: 10.3390/pharmaceutics13040492.
118. Ard, R., J.-C. Maillet, E. Daher, M. Phan, R. Zinoviev, R.J. Parks, and S.H Gee (2021) PKCα-mediated phosphorylation of the diacylglycerol kinase ζ MARCKS domain switches cell migration modes by regulating interactions with Rac1 and RhoA. J Biol Chem. 296:100516. doi: 10.1016/j.jbc.2021.100516.
119. Roberto, J., K.L. Poulin, R.J. Parks and P.O. Vacratsis (2021) Label-free quantitative proteomic analysis of extracellular vesicles released from fibroblasts derived from patients with spinal muscular atrophy Proteomics e2000301. doi: 10.1002/pmic.202000301.
120. Clarkin, R., J. Del Papa and R.J. Parks (2021) The genome position of a therapeutic transgene strongly influences the level of expression in an armed oncolytic human adenovirus vector. Virology 561:87-97.
121. Han, C.Y., D.A. Patten, S.I. Kim, J.J. Lim, D.W. Chan, M.K.Y. Siu, Y. Han, E. Carmona, R.J. Parks, C. Lee, L.-J. Di, Z. Lu, K.K.L. Chan, J.-L. Ku, E.A. Macdonald, B.C. Vanderhyden, A.-M. Mes-Masson, H.Y.S. Ngan, A.N.Y. Cheung, Y.S. Song, R.C. Bast Jr., M.-E. Harper and B.K. Tsang (2021) Nuclear HKII–P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers 13(14):10.3390/cancers13143399.
2023
122. Jennings, M.R. and R.J. Parks (2023) Human adenovirus gene expression and replication is regulated through dynamic changes in nucleoprotein structure throughout infection. Viruses 15(1):161.
123. Smith I.C., S. Chakraborty, P.R. Bourque, M.L. Sampaio, G. Melkus, H. Lochmüller, J. Woulfe, R.J. Parks, B. Brais, and J. Warman-Chardon (2023) Emerging and established biomarkers of oculopharyngeal muscular dystrophy. Neuromuscul Disord. 33(11):824-834. doi: 10.1016/j.nmd.2023.09.010.
124. René C.A. and R.J. Parks (2023) Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy. Pharmaceutics 15(6):1764. doi: 10.3390/pharmaceutics15061764.
125. Boulton S, M.J.F. Crupi, S. Singh, M.E. Carter-Timofte, T. Azad, B.C. Organ, X. He, R. Gill, S. Neault, T. Jamieson, J. Dave, N. Kurmasheva, B. Austin, J. Petryk, R. Singaravelu, B.Z. Huang, N. Franco, K. Babu, R.J. Parks, C.S. Ilkow, D. Olagnier, and J.C. Bell (2023) Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development. J Biol Chem. 299(6):104749. doi: 10.1016/j.jbc.2023.104749.
2024
126. René C.A. and R.J. Parks (2024) Bioengineering extracellular vesicle cargo for optimal therapeutic efficiency. Mol Ther Methods Clin Dev. 2024 Apr 26;32(2):101259. doi: 10.1016/j.omtm.2024.101259.
All Other Publications
_______________________________________________________________________________________
1990-1995
1. Pakuts, A.P., R.J. Parks, C.J. Paul, S.J. Bujaki and R.W. Mueller (1990) Ketoconazole induced hepatic lysosomal phospholipidosis: the effect of concurrent barbiturate treatment. Res. Commun. Chem. Pathol. Pharmacol. 67:55-62.
2. Fisher, C.A., R.J. Parks, M.L. Lauzon and D.H. Evans (1991) Heteroduplex DNA formation is associated with replication and recombination in poxvirus infected cells. Genetics 129:7-18.
3. Parks, R.J. and D.H. Evans (1991) Marker effects associated with the recom¬bination of insertion and deletion mutations in poxvirus infected cells. Virol. 184:299-309.
4. Parks, R.J. and D.H. Evans (1991) Effect of marker distance and orientation on recombinant formation in poxvirus infected cells. J. Virol. 65:1263-1272.
5. Parks, R.J., P.J. Krell, J.B. Derbyshire and E. Nagy (1994) Studies of Fowlpox virus recombination in the generation of recombinant vaccines. Virus Res. 32:283-297.
6. Parks, R.J., B. Lichtey, C. Karakis and D.H. Evans (1994) Characterization of the Shope fibroma virus DNA ligase gene. Virol. 202:642-650.
1996
7. Palaniyar, N., C. Fisher, R. Parks and D.H. Evans (1996) SFV topoisomerase: sequence specificity in a genetically mapped interval. Virol. 221:351-354.
8. Parks, R.J. and D.H. Evans (1996) The effect of transcription on genetic recombination in poxvirus-infected cells. Virus Res. 41:11-23.
9. Parks, R.J., L Chen, M. Anton, U. Sankar, M. Rudnicki and F.L. Graham (1996) A helper dependent adenovirus vector system: removal of helper virus by Cre mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93:13565 13570.
1997
10. Parks, R.J. and F.L. Graham (1997) A helper dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J. Virol. 71:3293 3298.
1998
11. Scheidner, G., N. Morral, R.J. Parks, Y. Wu, S.C. Koopmans, C. Langston, F.L. Graham, A.L. Beaudet and S. Kochanek (1998) Genomic DNA transfer with a high capacity adenovirus vector results in improved in vivo expression and decreased toxicity. Nature Genet. 8:180-183.
12. Morsy, M.A., M.-C. Gu, S. Motzel, J. Zhao, L. Franlin, J. Lin, H. Allan, R.J. Parks, F.L. Graham, S. Kochanek, A.J. Bett and C.T. Caskey (1998) An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA 95:7866-7871.
13. Parks, R.J., C.F. Winchcombe-Forhan, A.M. DeLange, X. Xing and D.H. Evans (1998) DNA ligase gene disruptions can depress viral growth and replication in poxvirus infected cells. Virus Res.56:135 147.
14. Morral, N., R.J. Parks, H. Zhou, C. Langston, G. Scheidner, J. Quinones, F.L. Graham, S. Kochanek and A.L. Beaudet (1998) High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Human Gene Ther. 9:2709 2716.
1999
15. Recchia, A., R.J. Parks, S. Lamartina, C. Toniatti, L. Pieroni, F. Palombo, G. Ciliberto, R. Cortese, N. LaMonica, S. Colloca (1999) Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc. Natl. Acad. Sci. USA. 96:2615-2620.
16. Pastore, L., N. Morral, R. Garcia, H. Zhou, R.J. Parks, S. Kochanek, F.L. Graham, B. Lee, and A.L. Beaudet (1999) Use of tissue-specific promoter reduces immune response to the transgene in adenoviral vectors. Human. Gene Ther. 10:1773-1781.
17. Morral, N., W. O'Neal, K. Rice, M. Leland, J. Kaplan, P.A. Piedra, H. Zhou, R.J. Parks, R. Velji, E. Aguilar-Cordova, S. Wadsworth, F.L. Graham, S. Kochanek, K.D. Carey, A.L. Beaudet (1999) Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA 96:12816 21.
18. Ng, P., R.J. Parks, D. Cummings, C. Evelegh, U. Sankar, and F.L. Graham (1999) A high efficiency Cre/loxP based system for construction of adenoviral vectors. Hum Gene Ther. 10:2667 2672.
19. Parks, R.J., C.M. Evelegh, and F.L. Graham (1999) Use of helper-dependent adenoviral vectors of alternative serotype permits repeat vector administration. Gene Therapy. 6:1565-1573.
20. Parks, R.J., J.L. Bramson, Y. Wan, C.L. Addison, and F.L. Graham (1999) Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J. Virol. 73:8027-8034.
21. Parks, R.J. and J. L. Bramson (1999) Adenoviral vectors: prospects for gene delivery to the central nervous system. Gene Therapy 6:1349-1350.
2000
22. Ng, P., R.J. Parks, D.T. Cummings, C.M. Evelegh and F. L. Graham (2000) An enhanced system for construction of adenoviral vectors by the two plasmid rescue method. Hum. Gene Ther. 10:2667-2672.
23. O'Neal, W.K., H. Zhou, N. Morral, C. Langston, R.J. Parks, F.L. Graham, S. Kochanek, A.L. Beaudet (2000) Toxicity associated with repeated administration of first-generation adenoviral vectors is not induced by a helper-dependent vector. Molecular Medicine 6:179-195.
24. Cregan, S.P., J. MacLaurin, T.F. Gendron, S.M. Callaghan, D.S. Park, R.J. Parks, F.L. Graham, P. Morley and R.S. Slack (2000) Helper-dependent adenovirus vectors: their use as a gene delivery system to neurons. Gene Therapy 7:1200-1209.
25. Parks, R.J. (2000) Improvements in adenoviral vector technology: overcoming barriers for gene therapy. Clinical Genetics 58:1-19.
2001
26. Ng, P., C. Beauchamp, C. Evelegh, R. Parks, and F.L. Graham (2001) Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Molecular Therapy 3:809-815.
2002
27. Hubberstey, A.V., M. Pavliv and R.J. Parks (2002) Cancer therapy utilizing an adenoviral vector expressing only E1A. Cancer Gene Therapy 9:321-329.
28. Amalfitano, A., and R.J. Parks (2002) Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Current Gene Therapy 2:111-133.
29. Ng, P., R.J. Parks, and F.L. Graham (2002) Preparation of helper-dependent adenoviral vectors. Methods Mol Med. 2002;69:371-88.
2003
30. Didonato, C.J., R.J. Parks, and R. Kothary (2003) Development of a gene therapy strategy for the restoration of survival motor neuron (SMN): implications for SMA therapy. Human Gene Therapy 14:179-188.
31. Wellington, C.L., L.R. Brunham, S. Zhou, R. Singaraja, H. Visscher, A. Gelfer, C. Ross, E. James, G. Liu, M. Huber, Y.-Z. Yang, R.J. Parks, A. Groen, J. Najib-Fruchart, and M.R. Hayden (2003) Alterations of plasma lipids in mice via adenoviral mediated hepatic overexpression of human ABCA1. J. Lipid Res. 44:1470-1480.
32. Ross, P.J. and R.J. Parks (2003) Oncolytic adenovirus: getting there is half the battle. Molecular Therapy 8:705-706.
2004
33. Sargent, K., C. Evelegh, F.L. Graham, and RJ Parks (2004) Development of a size restricted pIX helper virus for amplification of helper dependent adenovirus vectors. Gene Therapy 11:504-511.
34. Bramson, J.L., N. Grinshtein, R.A. Meulenbroek, J. Lunde, D. Kottachchi, I.A. Lorimer, B.J. Jasmin, and R.J. Parks (2004) Helper-dependent adenoviral vectors containing modified fibre for improved transduction of developing and mature muscle cells. Human Gene Therapy 15:179-188.
35. Meulenbroek, R.M., K.S. Sargent, J. Lunde, B.J. Jasmin, and R.J. Parks (2004) Use of adenovirus pIX to display large polypeptides in the virion – generation of fluorescent virus through the incorporation of pIX-GFP. Mol. Ther. 9:617-624.
36. Sargent, K.L., R.A. Meulenbroek, and R.J. Parks (2004) Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. J. Virol. 78:5032-5037.
37. Muruve, D.A., M.J. Cotter, A.K. Zaiss, L.R. White, Q. Liu, T. Chan, S.A. Clark, P.J. Ross, R.A. Meulenbroek, G.M. Maelandsmo, and R.J. Parks (2004) Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses J. Virol. 78:5966-5972.
38. Chambers, K.A., R.J. Parks, and J.B. Angel (2004) Disruption of map kinase activation and nuclear factor binding to the IL-12 p40 promoter in HIV-infected myeloid cells. Clinical and Experimental Immunology 137:329-340.
39. Huh, M.S., M.H. Parker, A. Scime, A. Berns, R.J. Parks, and M.A. Rudnicki (2004) Rb is required for progression through myogenic differentiation but not maintenance of terminal differentiation. J. Cell. Biol. 166:865-876.
40. Brown, R.J., A. Gauthier, R.J. Parks, R. McPherson, D.L. Sparks, J.R. Schultz, and Z. Yao (2004) Severe hypoalphalipoproteinuria in mice expressing human hepatic lipase deficient in binding to heparin sulfate proteoglycan. J. Biol. Chem. 279:42403-42409.
2005
41. Maelandsmo, G.M., P.J. Ross, M. Pavliv, R.A. Meulenbroek, C. Evelegh, F.L. Graham, and R.J. Parks (2005) Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice J. Gene Medicine 7:307-315.
42. Parks, R.J. (2005) Adenovirus protein IX: a new look at an old protein. Molecular Therapy 11:19-25.
43. Chakkalakal, J.V., J. Thompson, R.J. Parks, and B.J. Jasmin (2005) Molecular, cellular and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB J. 19:880-891.
44. Deschênes-Furry, J.L., G. Bélanger, J. Mwanjewe, J.A. Lunde, R.J. Parks, N. Perrone-Bizzozero, and B.J. Jasmin (2005) The RNA-binding protein HuR binds to acetylcholinesterase transcripts and regulates their expression in differentiating skeletal muscle cells. Journal of Biological Chemistry 280:25361-25368.
45. Yakubchyk, Y., H. Abramovici, C. Obagi, R.J. Parks, M.K. Topham, and S.H. Gee (2005) Regulation of neurite outgrowth in N1E-115 cells through spatial control of diacylglycerol kinase-ζ and Rac1 by syntrophins. Molecular and Cellular Biology 25:7181-7192.
2006
46. Michaud, J.-L.R., K.M. Chaisson, R.J. Parks, and C.R.J. Kennedy (2006) FSGS-associated mutant alpha-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney International 70:1054-1061.
2007
47. Deschênes-Furry, J.L., K. Mousavi, F. Bolognani, R.L. Neve, R.J. Parks, N.I. Perrone-Bizzozero, and B.J. Jasmin (2007) The RNA-binding protein HuD binds acetylcholinesterase mRNA in neurons and regulates its gene expression following axotomy. J. Neurosci. 27:665-75.
2008
48. Muruve, D.A., V.Petrilli, A.K. Zaiss, L.R. White, S.A. Clark, P.J. Ross, R.J. Parks, and J. Tschopp (2008) Recognition of cytosolic microbial and host DNA by the inflammasome triggers an innate immune response. Nature 452:103-107.
2009
49. Smith, A.C., K.L. Poulin, and R.J. Parks (2009) DNA genome size affects the stability of the adenovirus virion. J. Virol. 83:2025-2028.
50. Abramovici, H., P. Mojtabaie, R.J. Parks, X.-P. Zhong, G.A. Koretzky, M.K. Topham and S.H. Gee (2009) Defective cell migration and membrane ruffling in diacylglycerol kinas?e-z-deficient fibroblasts due to decreased Pak1 phosphorylation and impaired dissociation of Rac1 from its inhibitor RhoGDI. Mol. Biol. Cell. 20:2049-59.
51. Ross P.J., M.A. Kennedy and R.J. Parks (2009) Host cell detection of non-coding stuffer DNA contained in helper-dependent adenovirus vectors leads to epigenetic repression of transgene expression. J. Virol. 83:8409-17.
52 Ross, P.J. and R.J. Parks (2009) Construction and characterization of adenovirus vectors. Cold Spring Harbor Protocols doi:.1101/pdb.prot5011
53. Storbeck, C.J., S. Wagner, P. O'Reilly, M. McKay, R.J. Parks, H. Westphal and L.A. Sabourin (2009) The Ldb1 and Ldb2 transcriptional co-factors interact with the Ste20-like kinase SLK and regulate cell migration. Mol. Biol. Cell. 20:4174-4182.
54. Kennedy, M.A. and R.J. Parks (2009) Adenovirus virion stability and the viral genome: size matters. Mol. Ther. 17:1664-1666.
55. Venderova, K., G. Kabbach, E. Abdel-Messih, Y. Zhang, R.J. Parks, Y. Imai, S. Gehrke, J. Ngsee, M.J. LaVoie, R. Slack, Y. Rao, Z. Zhang, B. Lu, M.E. Haque, and D.S. Park (2009) Leucine-rich repeat kinase interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Human Molecular Genetics 18:4390-404.
56. Finn, J.D., J. Bassett, J.B. Millar, N. Grinshtein, T.C. Yang, R. Parsons, C. Evelegh, Y. Wan, R.J. Parks, and J.L. Bramson (2009) Persistence of transgene expression influences CD8+ T cell expansion and maintenance following immunization with recombinant adenovirus. J. Virol 83:12027-36.
2010
57. Sundaram, M, S. Zhong, M.-B. Khalil, P.H. Links, Y. Zhao, J. Iqbal, M. Hussain, R.J. Parks, Y. Wang, and Z. Yao (2010) Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid rich conditions. J. Lipid Res. 51:150-161.
58. Boucher, J.G., K.A. Parato, F. Frappier, W. Ma, N. Gajanayaka, R.J. Parks, A. Kumar, J.B Angel (2010) Disparate regulation of LPS-induced MAPK signalling and IL-12p40 expression between different myeloid cell types with and without HIV infection. Viral Immunology 23:17-28.
59. Li, L., S. Wang, A. Jezierski, L. Moalim-Nour, K. Mohib, R.J. Parks, S.F. Retta, L. Wang (2010) A unique interplay between Rap1 and E-cadherin in the endocytic pathway regulates cell fate decisions of human embryonic stem cells. Stem Cells 28:247-57.
60. Poulin, K.L., R.M. Lanthier, A.C. Smith, C. Christou, M. Risco-Quiroz, K.L. Powell, R.W. O'Meara, R. Kothary, I.A. Lorimer, R.J. Parks (2010) Retargeting of adenovirus vectors through fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol. 84:10074-86.
2011
61. Christou, C., and R.J. Parks (2011) Rational design of murine secreted alkaline phosphatase for enhanced performance as a reporter gene in mouse gene therapy preclinical studies. Human Gene Therapy 22:499-506.
62. Bamji-Mirza, M., M. Sundaram, S. Zhong, E.F. Yao, R.J. Parks and Z. Yao (2011) Secretion of lipid-poor VLDL particles from McA-RH7777 cells expressing human hepatic lipase. J Lipid Res. 52:540-548.
63. Beug, S.T., R.J. Parks, H.M. McBride and V.A. Wallace (2011) Trafficking of the Sonic hedgehog morphogen to the regulated secretory pathway in mammalian neurons. Mol Cell Neurosci 46:583-596.
64. Ross, P.J., M.A. Kennedy, C. Christou, M. Risco Quiroz, K.L. Poulin and R.J. Parks (2011) Assembly of helper-dependent adenovirus DNA into chromatin promotes efficient gene expression. J. Virol. 85:3950-3958.
65. Qin, W.¬, M. Sundaram, Y. Wang, H. Zhou, S. Zhong, C.-C. Chang, S. Manhas, E.F. Yao, R.J. Parks, P.J. McFie, S.J. Stone, Z.G. Jiang, C. Wang¬, D. Figeys, W. Jia¬, and Z. Yao (2011) Missense mutation in APOC3 within the C-terminal lipid-binding domain of human apoCIII results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins. J. Biol. Chem. 286:27769-80.
66. Poulin, K.L., G. Tong, O. Vorobyova, M. Pool, R. Kothary, R.J. Parks (2011) Use of Cre/loxP recombination to swap cell binding motifs on the adenoviral capsid protein IX. Virology 420:146–155.
2012
67. Giberson, A.N., A.R. Davidson, and R.J. Parks (2012) Chromatin structure of adenovirus DNA throughout infection. Nucleic Acids Res. 40:2369-76.
68. Anker, J.J., S. Brimijoin, Y. Gao, L. Geng, N.E. Zlebnik, R.J. Parks, and M.E. Carroll (2012) Cocaine hydrolase encoded in viral vectors blocks the reinstatement of cocaine seeking in rats for 6 months. Biological Psychiatry 71:700-5.
69. Ard, R. H. Abramovici, J.-C. Maillet, A. Fottinger, M. Byham, T.A. Iqbal, A. Yoneda, J.R. Couchman, R.J. Parks, and S.H. Gee (2012) Diacylglycerol kinase-zeta regulates RhoA activation via a kinase-independent scaffolding mechanism. Molecular Biology of the Cell 23(20):4008-19.
70. Huh, M.S., T. Price-O'Dea, D. Ouazia, B.C. McKay, R.J. Parks, M.A. Rudnicki, and D.J. Picketts (2012) Genomic Instability as a Disease Causing Mechanism in Muscle Specific Atrx Knockout Mice. Journal of Clinical Investigation 122(12):4412-23.
71. Carroll, M.E., N. Zlebnik, J.J. Anker, T. Kosten, F. Orson, X. Shen, B. Kinsey, R.J. Parks, Y. Gao, and S. Brimijoin (2012) Combined Cocaine Hydrolase Gene Transfer and Anti-Cocaine Vaccine Synergistically Block Cocaine-Induced Locomotion. PLoS One 7(8):e43536.
72. Conte, D., M.S. Huh, E. Goodall, M. Delorme, R.J. Parks and D.J. Picketts (2012) Loss of Atrx Sensitizes Cells to DNA Damaging Agents Through p53-Mediated Death Pathways. PLoS One 7(12):e52167
2013
73. Knipe, D.M., P.M. Lieberman, J.U. Jung, A.A. McBride, K.V. Morris, M. Ott, D. Margolis, A. Nieto, M. Nevels, R.J. Parks and T. Kristie (2013) Snapshots: Chromatin Control of Viral Infection. Virology 435:141-156.
74. Goulet, B.B., R. Kothary and R.J. Parks (2013) At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression. Current Molecular Medicine 13(7):1160-74.
75. Goulet, B.B., R. Kothary and R.J. Parks (2013) Supraphysiological expression of Survival Motor Neuron protein from an adenovirus vector does not adversely affect cell function. Biochemistry and Cell Biology 91(4):252-64.
76. Wong, C.M., E.R. McFall, J.K. Burns and R.J. Parks (2013) The role of chromatin in adenoviral vector function. Viruses 5:1500-1515.
77. Geng, L., Y. Gao, X. Chen, S. Hou, C.-G. Zhan, Z. Radic, R.J. Parks, S.J. Russell, L. Pham, and S. Brimijoin (2013) Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity. PLoS One 8(6):e67446.
78. von Maltzahn, J., A.E. Jones, RJ. Parks, and M.A. Rudnicki (2013) Pax7 is critical for the normal function of satellite cells in adult skeletal muscle. PNAS 110:16474-9.
2014
79. Holterman, C., J.-F. Thibodeau, C. Towaij, A. Gutsol, R.J. Parks, M. Cooper, R. Touyz and C. Kennedy (2014) Nephropathy and elevated blood pressure in transgenic mice with podocyte-specific Nox5 expression. Journal of the American Society of Nephrology 25:784-97.
80. Zlebnik, N.E., S. Brimijoin, Y. Gao, A.T. Saykao, R.J. Parks, and M.E. Carroll (2014) Long-term reduction of cocaine self-administration in rats treated with adenoviral vector-delivered cocaine hydrolase: evidence for enzymatic activity. Neuropsychopharmacology 9:1538-46.
81. Puppo, A., G. Cesi, E. Marrocco, P. Piccolo, S. Jacca, D.M. Shayakhmetov, R.J. Parks, B.L. Davidson, S. Colloca, N. Brunetti-Pierri, P. Ng, G. Donofrio, and A. Auricchio (2014) Retinal transduction profiles by high-capacity viral vectors. Gene Therapy 21:855-865.
82. Murthy, V., Y. Gao, L. Geng, N.K. LeBrasseur, T.A. White, R.J. Parks, and S. Brimijoin (2014) Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice. Vaccine 32:4155-62.
83. McFall, E.R., L.M. Murray, J.A. Lunde, B.J. Jasmin, R. Kothary, and R.J. Parks (2014) A reduction in the human adenovirus virion size through use of a shortened fibre protein does not enhance muscle transduction following systemic or localized delivery in mice. Virology 468-470:444-453.
84. Saha, B., C.M. Wong, and R.J. Parks (2014) The adenovirus genome contributes to the structural stability of the virion. Viruses 6:3563-3583.
2015
85. Chen, V.P., Y. Gao, L. Geng, R.J. Parks, T. Tchkonia, Y.-P. Pang, S. Brimijoin (2015) Plasma butyrylcholinesterase regulates ghrelin to control aggression PNAS 112:2251-6.
86. Ard, R., K. Mulatz, J.L. Pomoransky, R.J. Parks, L. Trinkle-Mulcahy, J.C. Bell, and S.H. Gee (2015) Regulation of Macropinocytosis by Diacylglycerol Kinase ζ. PLoS ONE 10(12):e0144942. doi: 10.1371/journal.pone.0144942.
2016
87. Wong, C.M., K.L. Poulin, G. Tong, C. Christou, M.A. Kennedy, T. Falls, J.C. Bell and R.J. Parks (2016) Adenovirus-mediated expression of the p14 fusion-associated small transmembrane protein promotes cancer cell fusion and apoptosis in vitro but does not provide therapeutic efficacy in a xenograft mouse model of cancer PLoS ONE 11(3):e0151516. doi: 10.1371/journal.pone.0151516.
88. Al-Khalaf, M., L. Blake, B. Larsen, S. Brunette, R. Parks, M. Rudnicki, P. McKinnon, F. Dilworth, R. Bell and L. Megeney (2016) Temporal activation of XRCC1 mediated DNA repair is essential for muscle differentiation. Cell Discovery 2:15041 doi:10.1038/celldisc.2015.41.
89. Smethells, J.R., N. Swalve, S. Brimijoin, Y. Gao, R.J. Parks, A. Greer, and M.E. Carroll (2016) Long-term blockade of cocaine self-administration and locomotor activation in rats by an adenoviral vector-delivered cocaine hydrolase. J Pharmacol Exp Ther. 2016 Mar 11. pii: jpet.116.232504.
90. Burns, J.K., R. Kothary and R.J. Parks (2016) Opening the window: The case for carrier and perinatal screening for spinal muscular atrophy. Neuromuscular Disorders 26:551-9.
91. Warman Chardon, J., B.J. Jasmin, R. Kothary and Parks, R.J., (2016) Report on the 3rd Ottawa International Conference on Neuromuscular Biology, Disease and Therapy – September 24-26, 2015, Ottawa, Canada. Journal of Neuromuscular Diseases. 3:431–442.
92. Wong, C.M., L.A. Nash, J. Del Papa, K.L. Poulin, T. Falls, J.C. Bell, and R.J. Parks (2016) Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer. Cancer Gene Therapy 23(10):355-364.
93. Alvarez-Saavedra M., Y. De Repentigny, D. Yang, R.W. O'Meara, K. Yan, L.E. Hashem, L. Racacho, I. Ioshikhes, D.E. Bulman, R.J. Parks, R. Kothary, and D.J. Picketts, (2016) Voluntary Running Triggers VGF-Mediated Oligodendrogenesis to Prolong the Lifespan of Snf2h-Null Ataxic Mice. Cell Rep.11:17(3):862-875.
94. Nash, L.A., J.K. Burns, J. Warman Chardon, R. Kothary and R.J. Parks (2016) Spinal Muscular Atrophy: More than a disease of motor neurons? Current Molecular Medicine 16(9):779-792.
2017
95. Del Papa, J. and R.J. Parks (2017) Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents. Viruses 19;9(1). pii: E13. doi: 10.3390/v9010013.
96. Saha, B. and R.J. Parks (2017) Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cells. PLoS One. 2017 Jul 10;12(7):e0181012.
97. Eid, W., K. Dauner, K.C. Courtney, A. Gagnon, R.J. Parks, A. Sorisky, and X. Zha. (2017) mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells. Proc Natl Acad Sci U S A. 2017 Jul 10. pii: 201705304. doi: 10.1073/pnas.1705304114.
98. Sundaram, M., K.R. Curtis, M.A. Alipour, N.D. LeBlond, K.D. Margison, R.A. Yaworski, R.J. Parks, A.D. McIntyre, R.A. Hegele, M.D. Fullerton, and Z. Yao (2017) The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation. J Lipid Res. 58(11):2188-2196..
99. Nash, L.A, E.R. McFall, A.M. Perozzo, M. Turner, K.L. Poulin, Y. De Repentigny, J.K. Burns, H.J. McMillan, J. Warman Chardon, D. Burger, R. Kothary, and R.J. Parks (2017) Survival Motor Neuron Protein is Released from Cells in Exosomes: A Potential Biomarker for Spinal Muscular Atrophy. Scientific Reports 7(1):13859.
2018
100. Parks, R.J. and E. Gussoni (2018) Building immune tolerance through DNA vaccination. Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9652-9654. doi: 10.1073/pnas.1813461115.
101. Giberson, A.N., B. Saha, K. Campbell, C. Christou, K.L. Poulin, and R.J. Parks (2018) Human adenoviral DNA association with nucleosomes containing histone variant H3.3 during the early phase of infection is not dependent on viral transcription or replication. Biochem. and Cell. Biol. 96(6):797-807.
102. Warman Chardon, J., B.J. Jasmin, R. Kothary and R.J. Parks (2018) Report on the 4th Ottawa International Conference on Neuromuscular Disease and Biology - September 5-7, 2017, Ottawa, Canada. Journal of Neuromuscular Diseases. 5(4):539-552.
2019
103. Saha, B. and R.J. Parks (2019) Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses human adenovirus gene expression and replication. J Virol. 93(12). pii: e00088-19. doi: 10.1128/JVI.00088-19.
104. Del Papa, J., J. Petryk, J.C. Bell, and R.J. Parks (2019) An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate In Vivo. Molecular Therapy Oncolytics. 14:107-120.
105. Zhang, Y., C.Y. Han, F.G. Duan, X.X. Fan, X.J. Yao, R.J. Parks, Y.J. Tang, M.F. Wang, L. Liu, B.K. Tsang, E.L. Leung (2019) p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling. Cancer Cell Int. 2019 Jul 19;19:188. doi: 10.1186/s12935-019-0910-2.
106. Han, C.Y., D.A. Patten, S.I. Kim, J.J. Lim, M.K.Y. Siu, Y. Han, E. Carmona, R. Parks, C. Lee, K.K. L. Chan7, J.-L. Ku, E.A. Macdonald, B. Vanderhyden, A.M. Mes-Masson, H.Y. S. Ngan, A. Cheung, Y.S. Song, M.-E. Harper and B.K. Tsang. p53 promotes chemoresponsiveness by regulating Hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer. Molecular Carcinogenesis 2019 Sep 4. doi: 10.1002/mc.23106.
107. Saha, B., O. Varette, W.L. Stanford, J.-S. Diallo and R.J. Parks. Development of a novel screening platform for the identification of small molecule inhibitors of human adenovirus. 2019. Virology 538:24-34.
2020
108. Poulin, K.L, E.R. McFall, G. Chan, N.B. Provost, C. Christou, A.C. Smith, R.J. Parks (2020) Fusion of large polypeptides to human adenovirus type 5 capsid protein IX can compromise virion stability and DNA packaging capacity. J Virol. 17;94(17):e01112-20.
109. Del Papa, J., R.G. Clarkin, R.J. Parks (2020) Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic. Cancer Gene Therapy doi: 10.1038/s41417-020-0192-9.
110. Saha, B. and R.J. Parks (2020) Recent Advances in Novel Antiviral Therapies against Human Adenovirus. Microorganisms 2020, 8, 1284.
111. Jennings, M.R. and R.J. Parks (2020) Antiviral Effects of Curcumin on Adenovirus Replication. Microorganisms 2020, 8, 1524; doi:10.3390/microorganisms8101524.
112. Tzelepis, F., H. Kaur Birdi, A. Jirovec, S. Boscardin, C. Tanese de Souza, M. Hooshyar, A. Chen, K. Sutherland, R. Parks, J. Werier, and J.-S. Diallo (2020) Oncolytic rhabdovirus vaccine boosts chimeric anti-DEC205 priming for effective cancer immunotherapy. Molecular Therapy Oncolytics. doi.org/10.1016/j.omto.2020.10.007.
113. Jennings, M.R. and R.J. Parks (2020) Curcumin as an antiviral agent. Viruses 12:1242; doi.org/10.3390/v12111242.PubMed Listings
